Keiichi Fujiwara
Expertise in
22
conditions

Keiichi Fujiwara

Crest, 
Tokyo, JP 
Expertise in
22
conditions
Crest, 
Tokyo, JP 

Overview

Keiichi Fujiwara practices practicing medicine in Tokyo, Japan.

Mr. Fujiwara is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Ovarian Cancer, Autoimmune Hepatitis, Liver Failure, Liver Transplant, and Stent Placement.

He is actively involved in clinical research, co-authoring 418 peer reviewed articles and participating in 4 clinical trials.

Gender

Male

Locations

Crest, Tokyo, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)
Enrollment Status: Active_not_recruiting
Publish Date: December 30, 2025
Intervention Type: Other, Drug, Biological
Study Drugs: Bevacizumab, Carboplatin, Docetaxel, Gemcitabine Hydrochloride, Paclitaxel
Study Phase: Phase 3
ATHENA (A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)
ATHENA (A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)
Enrollment Status: Active_not_recruiting
Publish Date: June 24, 2025
Intervention Type: Drug
Study Drugs: Rucaparib, Nivolumab
Study Phase: Phase 3
Comparative Analysis of CA-IX, p16, Proliferative Markers, and Human Papilloma Virus (HPV) in the Diagnosis of Significant Cervical Lesions in Patients With a Cytologic Diagnosis of Atypical Glandular Cells (AGC)
Comparative Analysis of CA-IX, p16, Proliferative Markers, and Human Papilloma Virus (HPV) in the Diagnosis of Significant Cervical Lesions in Patients With a Cytologic Diagnosis of Atypical Glandular Cells (AGC)
Enrollment Status: Unknown
Publish Date: May 03, 2024
Intervention Type: Other
Study Phase: Not Applicable
A Phase III Randomized Trial of Pulse Actinomycin-D Versus Multi-day Methotrexate for the Treatment of Low-Risk Gestational Trophoblastic Neoplasia
A Phase III Randomized Trial of Pulse Actinomycin-D Versus Multi-day Methotrexate for the Treatment of Low-Risk Gestational Trophoblastic Neoplasia
Enrollment Status: Completed
Publish Date: August 12, 2022
Intervention Type: Other, Drug, Biological
Study Drugs: Dactinomycin, Leucovorin Calcium, Methotrexate
Study Phase: Phase 3
View 3 Less Clinical Trials

417 Total Publications

Diagnosis of Synchronous Primary Lung Cancers Using EBUS-TBNA and BDBD-Assisted Transbronchial Biopsy During a Single Bronchoscopic Procedure: A Case Report.
Diagnosis of Synchronous Primary Lung Cancers Using EBUS-TBNA and BDBD-Assisted Transbronchial Biopsy During a Single Bronchoscopic Procedure: A Case Report.
Journal: Respirology case reports
Published: July 23, 2026

Frequently Asked Questions about Keiichi Fujiwara

Is Keiichi Fujiwara a top-rated expert for Ovarian Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Keiichi Fujiwara is classified as an Elite expert for Ovarian Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Keiichi Fujiwara participate in research or clinical trials?

Yes. Keiichi Fujiwara has published 417 articles and abstracts on conditions like Ovarian Cancer. You can view a list of Keiichi Fujiwara's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Fujiwara's expertise for a condition
ConditionClose
View All 16 Advanced Conditions
View All 73 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile